Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 5/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31396179 | 0.84 | RET (0.41) | KCNH2RETJAK3NR1H2NR1H3 | |
| SCHEMBL31401443 | 0.83 | MAPT (0.45) | ALDH1A1MAPTLMNARETJAK3 | |
| SCHEMBL1580680 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPTLMNAKCNH2MET | |
| SCHEMBL18186271 | 0.78 | MAPT (0.65) | ALDH1A1MAPTLMNANR1H2NR1H3 | |
| SCHEMBL25408763 | 0.77 | RET (0.41) | ALDH1A1MAPTLMNAKCNH2RET | |
| SCHEMBL31267843 | 0.76 | RET (0.45) | RETJAK3NR1H2NR1H3GPR119 | |
| SCHEMBL30270990 | 0.74 | RET (0.41) | RETJAK3NR1H2NR1H3 | |
| SCHEMBL27835006 | 0.74 | KCNH2 (0.38) | ALDH1A1MAPTLMNAKCNH2 | |
| SCHEMBL31396207 | 0.73 | RET (0.41) | RETJAK3NR1H2NR1H3GPR119 | |
| SCHEMBL20836796 | 0.73 | MAPT (0.47) | ALDH1A1MAPTLMNARETJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2025008060-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |